glp 1 and gip dual agonist GLP-1/GIP | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) Frontiers | Clinical perspectives on

Micronutrient Throughput

Graphical Abstract Keywords Metabolic dysfunction-associated steatotic liver disease, Glucagon-like peptide-1 receptor agonist, Clinical trial, Treatment, Metabolic dysfunction-associated steatohepatitis, Fibrosis Introduction Nonalcoholic fatty liver disease has been used to describe hepatic steatosis without significant alcohol intake

Manufacturers obtained pediatric exclusivities on 2 products after approval, which added 6 months to the existing patent expiration dates

Insulin resistance in type 1 diabetes: what is double diabetes and what are the risks

Diabetic Retinopathy: While Zepbound helps manage blood sugar levels, the risk remains if levels are not well-controlled, making regular eye exams crucial